Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.40 |
| ▸ | CA1 | P00915 | 8/20 | 0.40 |
| ▸ | CA9 | Q16790 | 5/20 | 0.40 |
| ▸ | CA5A | P35218 | 3/20 | 0.40 |
| ▸ | CA12 | O43570 | 6/20 | 0.35 |
| ▸ | CA7 | P43166 | 5/20 | 0.35 |
| ▸ | CA13 | Q8N1Q1 | 3/20 | 0.35 |
| ▸ | KIF11 | P52732 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 4/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.34 |
| ▸ | CA4 | P22748 | 2/20 | 0.31 |
| ▸ | CA6 | P23280 | 2/20 | 0.31 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.31 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.31 |
| ▸ | CES2 | O00748 | 1/20 | 0.31 |
| ▸ | CES1 | P23141 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | PTGES2 | Q9H7Z7 | 1/20 | 0.31 |
| ▸ | SOS1 | Q07889 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3601572 | 0.80 | CA1 (0.46) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL8182846 | 0.79 | VCAM1 (0.44) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL2378027 | 0.78 | PTGS2 (0.38) | CA2CA1PTGS1PTGS2CES2 | |
| SCHEMBL2378025 | 0.78 | CES2 (0.31) | CES2CES1 | |
| SCHEMBL16058359 | 0.77 | CA2 (0.45) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL14378236 | 0.77 | CYP3A4 (0.36) | PTGS2CES2CES1 | |
| SCHEMBL31503471 | 0.72 | TAAR1 (0.56) | CA2CA1CA9CA12RXFP1 | |
| SCHEMBL14426969 | 0.72 | CYP3A4 (0.40) | — | |
| SCHEMBL1364668 | 0.71 | PSEN1 (0.57) | CA2CA1CA9CA5ACA12 | |
| SCHEMBL3329020 | 0.71 | AKR1B1 (0.49) | CA2CA1CA9CA5ACES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100069350-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2010-03-18 | — | — | US | disclosed |
| EP-2044050-A1 | NEW PYRIDINE ANALOGUES | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| US-20080176827-A1 | New Pyridine Analogues VII 543 | ASTRAZENECA AB (SE) | 2008-07-24 | — | — | US | disclosed |
| WO-2008085118-A1 | PYRIDINE COMPOUNDS AND THEIR USE AS P2Y12 ANTAGONISTS. | ASTRAZENECA AB (SE) | 2008-07-17 | — | — | WO | disclosed |
| US-20080039437-A1 | New Pyridine Analogues III | ASTRAZENECA AB (SE) | 2008-02-14 | — | — | US | disclosed |
| WO-2008004946-A1 | NEW PYRIDINE ANALOGUES | ASTRAZENECA AB (SE) | 2008-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080176827-A1 | New Pyridine Analogues VII 543 | P2RY12, P2RY11, P2RY4 | CA2 2596/4885CA1 4603/4885CA9 3436/4885 |
| US-20080039437-A1 | New Pyridine Analogues III | P2RY12, P2RY1, P2RY11 | CA2 3764/4885CA1 4845/4885CA9 4563/4885 |
| US-20100069350-A1 | New Pyridine Analogues III | P2RY12, P2RY11, P2RY1 | CA2 2580/4885CA1 4624/4885CA9 3962/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.